Montrusco Bolton Investments Inc. lessened its stake in shares of OR Royalties Inc. (NYSE:OR – Free Report) by 17.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 332,958 shares of the basic materials company’s stock after selling 69,273 shares during the quarter. Montrusco Bolton Investments Inc. owned about 0.18% of OR Royalties worth $13,348,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its stake in OR Royalties by 152.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,256,583 shares of the basic materials company’s stock valued at $26,539,000 after acquiring an additional 758,815 shares in the last quarter. C WorldWide Group Holding A S lifted its holdings in shares of OR Royalties by 34.5% in the 2nd quarter. C WorldWide Group Holding A S now owns 104,974 shares of the basic materials company’s stock valued at $2,699,000 after purchasing an additional 26,942 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of OR Royalties by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 92,267 shares of the basic materials company’s stock valued at $2,384,000 after purchasing an additional 2,459 shares during the period. SG Americas Securities LLC grew its stake in OR Royalties by 24.8% during the 2nd quarter. SG Americas Securities LLC now owns 45,845 shares of the basic materials company’s stock worth $1,179,000 after buying an additional 9,100 shares during the last quarter. Finally, Cetera Investment Advisers lifted its stake in OR Royalties by 3.5% in the second quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock valued at $337,000 after buying an additional 440 shares during the last quarter. 68.52% of the stock is currently owned by institutional investors and hedge funds.
OR Royalties Trading Up 0.8%
Shares of OR opened at $45.81 on Thursday. OR Royalties Inc. has a twelve month low of $17.55 and a twelve month high of $47.75. The firm has a market capitalization of $8.59 billion, a P/E ratio of 42.03 and a beta of 0.76. The firm’s 50-day moving average is $40.61 and its two-hundred day moving average is $36.58.
OR Royalties Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Tuesday, March 31st will be given a $0.055 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.5%. OR Royalties’s dividend payout ratio (DPR) is currently 20.18%.
Analyst Ratings Changes
OR has been the subject of several research reports. Wall Street Zen downgraded shares of OR Royalties from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Scotiabank raised their price target on OR Royalties from $41.00 to $51.00 and gave the stock a “sector perform” rating in a report on Monday, January 26th. Raymond James Financial upgraded OR Royalties from a “market perform” rating to an “outperform” rating and set a $41.00 price target on the stock in a research report on Thursday, November 6th. TD Securities reaffirmed a “hold” rating on shares of OR Royalties in a research report on Monday. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $38.00 target price on shares of OR Royalties in a report on Sunday, December 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, OR Royalties has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.
Get Our Latest Report on OR Royalties
OR Royalties Company Profile
OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.
The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.
See Also
- Five stocks we like better than OR Royalties
- MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
- REVEALED: Something Big Happening Behind White House Doors
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Why the Smart Money Is Looking Beyond Single-Metal Stories
- Read this or regret it forever
Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.
